Generex Oncology Granted United States Patent for AE37 Peptide Vaccine
The AE37 immunotherapeutic vaccine is being developed by Antigen Express, Generex’s wholly-owned subsidiary, for use in patients with HER2 positive cancers. The vaccine is the subject of a randomized and controlled Phase II trial in patients with breast cancer; positive interim results, showing reduced relapse rates in patients receiving AE37, were released late in 2009. A Phase I trial of AE37 in patients with prostate cancer has been completed recently. A Phase I trial of AE37 in combination with another peptide vaccine is underway in patients with breast or ovarian cancer.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.